Drug Profile
Entecavir - Bristol-Myers Squibb
Alternative Names: Baraclude; BMS-200475; SQ 34676Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
- Discontinued Herpesvirus infections
Most Recent Events
- 16 Feb 2021 No development reported - Phase-III for Hepatitis B (In adolescents, In children) in Argentina (PO)
- 16 Feb 2021 No development reported - Phase-III for Hepatitis B (In adolescents, In children) in Belgium (PO)
- 16 Feb 2021 No development reported - Phase-III for Hepatitis B (In adolescents, In children) in Brazil (PO)